Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
MONDAY, June 8, 2026 (HealthDay News) -- Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with reduced risks for thromboembolic events, emergency department use, and mortality among adults with obesity and autoimmune diseases (AIDs), according to a study published online June 6 in the Journal of the American Heart Association to coincide with the annual meeting of the American Diabetes Association, held from June 5 to 8 in New Orleans.Hao Dai, Ph.D., from the Indiana University School of Medicine in Indianapolis, and colleagues conducted a retrospective cohort study, which emulated a target trial using 2014 to 2024 electronic health record data to examine the association between GLP-1 RA use and major adverse cardiovascular and thromboembolic event risk among adults with obesity and AID
Specific bacterial strains influence GLP-1 secretion from enteroendocrine cells
Protein And Fiber Targets For Hunger Control Post-GLP-1 With your appetite returning, hunger control becomes your top priority
The study comes from a single large health system in Ohio and Florida, which limits how broadly the findings can be applied across different demographics and care settings
Response is tracked by clinical assessment and photography, not by guesswork
US$ 25.18
US$ 20.34
US$ 20.55
US$ 27.80
US$ 23.80
US$ 29.77
US$ 25.33
US$ 27.76
US$ 29.75
